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Introduction
The airway macrophages (AMs) represent a heteroge-
neous group of cells that actively participate in the reg-
ulation of immune and inflammatory activities in lung
diseases [1-4]. The role of AMs in the pathogenesis of
allergic airway inflammation is complex and is often
determined by their activated phenotype [5]. To date,
the phenotypic features of AMs have been character-
ized in healthy and asthmatic subjects [6-10]. Howev-
er, the majority of reports were based on the analysis
of cells collected from bronchoalveolar lavage (BAL)
fluid, thus representing predominantly lower airways
[11]. Although this method provides a valuable tool for
assessment of airway cells, safety issues and access to
expert resources may limit its wide use in daily prac-
tice [12]. In contrast, sputum induction provides an
easy, repeatable and non-invasive tool for collection of
large numbers of bronchial macrophages (BMs)
together with eosinophils that serve as common mark-
ers of allergic inflammation [13]. BMs constitute 
a large population of AMs involved both in regulation
of innate immunity processes and allergic inflamma-
tion [14]. Sputum/bronchial phagocytes (among others
macrophages) express an inflammatory phenotype
even in healthy individuals and are functionally more
active than macrophages from lower airways [15]. In
another report, the same group described phagocytic
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Abstract: The role of different subpopulations of bronchial macrophages (BMs) in asthma pathogenesis has not yet been
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in steroid-naive asthmatic patients led to significant reduction of CD16 expression and enhancement of CD14 expression.
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dysfunction of BMs in asthmatic patients [16]. Thus
far, only few groups attempted to characterize and enu-
merate BM subsets in asthmatic patients and normal
atopic and non-atopic subjects [17,18]. However, less is
known about phenotypical features of different subpop-
ulations of BMs. This is mostly due to the fact that, in
general, the majority of reports on AMs were based on
the application of one- or two-color flow cytometry or
immunocytochemistry.  In this study, using a three-
color flow cytometric approach, we present the differ-
ences between asthmatic and healthy subjects in phe-
notype of BMs, also with regard to expression of recep-
tors for pro- and anti-inflammatory cytokines, namely
IL-4, IL-7 and IL-10. The counteracting roles of IL-4
and IL-10 in modulating allergic inflammation have
been widely described [19-21]. IL-7 has been postulat-
ed a "master regulator" of lymphocyte T-dependent
immune responses; however, it was also shown to exert
profound effects on populations of tissue macrophages
[22-25]. Recently, polymorphisms in genes encoding
IL-7R were associated with asthma symptoms, thus
suggesting the role for IL-7 and its receptor in asthma
pathogenesis [26]. Moreover, in a recent report we
demonstrated that IL-7R expression is decreased in
lungs of SIV-infected non-human primates, indicating
that IL-7R may be a marker of ongoing lung-associat-
ed inflammation [27]. Altogether, based on the above
information, we hypothesized that the levels of recep-
tors for IL-10, IL-4 and IL-7 might be important in
determining the susceptibility of BMs to immuno-
modulatory signals.  
In this study we attempted to correlate flow cyto-
metric phenotypic data regarding BMs with analyzed
on daily basis non-invasive markers of asthma severi-
ty, including exhaled nitric oxide. In addition, we
analysed the effects of short-term inhaled corticos-
teroid (ICS) treatment on the phenotype of BMs in
steroid-naive asthmatic patients. The data obtained
suggest, among others, an interesting correlation
between CD16 expression and eosinophilic airway
inflammation and between CD14 expression and IL-
10R expression on BMs. 
Materials and methods
Subjects. Subject characteristics are shown in Table 1. Severity of
asthma was classified according to GINA (Global Initiative for
Asthma) criteria [28]. Six patients with moderate persistent asthma
who were receiving treatment with only the inhaled long-acting
beta-adrenergic agonists were recruited as members of the
"steroid-naive" group. Those patients demonstrated >15%
improvement in FEV1 (forced expiratory volume in 1s) following
200µg of salbutamol.  Twelve patients with moderate persistent
asthma treated with a combination of medium doses of inhaled glu-
cocorticosteroids and long-acting beta-adrenergic agonists were
recruited to the "steroid-treated" group. Those patients were previ-
ously diagnosed in The Department of Allergology of Medical
University Hospital in Bialystok and subsequently treated for asth-
ma for a period of 7-18 years. All patients from both asthmatic
groups were atopic as defined by at least two positive skin prick
tests to common allergens. Current smokers and ex-smokers were
excluded from the study. 
In order to compare the bronchial macrophages between asth-
matic and nonasthmatic patients, we studied ten healthy nonatopic
nonsmoking volunteers who gave no history of asthma or of any
respiratory disease and who had normal lung function. The study
protocol was approved by the Bialystok Local Ethics Committee
(R-I-003/152/2005).
Induced sputum. Sputum was induced by the inhalation of hyper-
tonic saline as described elsewhere [29]. Three 7-min. inhalation
periods of 3, 4 and 5% hypertonic saline were administered fol-
lowing baseline spirometry. All subjects were premedicated with
200µg of inhaled salbutamol before saline inhalation. After each
inhalation period, an FEV1 value was measured for safety reasons
and the subjects were asked to blow their nose and rinse their
mouth with water, and to perform a "chesty-type" cough. The spu-
tum was expectorated into a sterile container that was placed on ice
throughout the procedure. 
Sputum was selected from saliva and processed immediately
after the collection as described by Pizzichini et al [29]. In brief,
sputum was weighed and incubated for 15 min at room tempera-
ture with a volume of 0.1% DTT (dithio-threitol) equal to four
times the weight (mg), and subsequently washed with four times
the plug weight in Dulbecco's PBS. The suspension was filtered
through a 48 µm-pore mesh filter and used for total cell count and
cell viability with the use of trypan blue. Visually identifiable squa-
mous epithelial cells were not counted or included in the total cell
count. Differential cell counts were performed on a minimum of
400 nonsquamous cells. 
Immunostaining. Aliquots of 100 µl of sputum cell suspension
(1×106 cells/ml) were incubated with 20 µl of monoclonal anti-
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Table 1. Subject characteristics.
Values are means ± standard deviation (SD). M-male, F-female. Asthmatic ICS (-) - asthmatic patients not receiving ICS. Asthmatic ICS (+) - asthmatic
patients treated with ICS. BUD - budesonide. LABA - long-acting β-agonists. FEV1- forced expiratory volume in 1s
bodies: anti-CD14 FITC or anti-CD14 PE (BD PharMingen, Bel-
gium), anti-CD16 PE-Cy5 or anti-CD16 FITC (BD PharMingen,
Belgium), anti-CD210 PE (IL-10R, BD PharMingen, Belgium),
anti-CD124 PE (IL-4R, BD PharMingen, Belgium), and anti-
CD127 PE (IL-7R, Immunotech, France). The cells were stained
with fluorochrome-conjugated mAbs for 30 min at room tempera-
ture, washed twice with phosphate-buffered saline, and fixed with
2% paraformaldehyde. 
Flow cytometric analysis. Flow cytometry was performed as
described previously [30,31]. A FACSCalibur cytometer (Becton
Dickinson Immunocytometry Systems) was  used to determine the
surface intensity of various antigens on sputum macrophages. In
order to ensure the reproducibility of the data generated, the settings
and calibration of the instrument fluorescence detectors were mon-
itored and optimized on each day of analysis according to manu-
facturer's recommendations, using CaliBRITE beads (BDIS). The
system linearity was evaluated using Sphero Rainbow Beads
(Spherotech, Libertyville, IL). The coefficient of variation (CV) of
all control beads used was less than 3% for scatter and fluorescence.
Flow cytometry data were collected in list mode and analyzed using
CellQuest software (BDIS). First, the bronchial macrophage popula-
tion was gated by a combination of forward and side scatter. The
gated cells were found positive for CD68 (data not shown). To assess
the expression of CD14, CD16, CD124, CD127, and CD210, the gate
was initially set with corresponding isotype and FMO (fluorescence-
minus-one) controls. In accordance with opinion of Roederer M et
al., the data are presented as the geometric mean fluorescence inten-
sity of bronchial macrophages coexpressing the above antigens [32].
An example of raw data for negative and positive control samples,
and, CD14 FITC and CD16 PE-Cy5 expression is shown on Fig. 1A
and, the raw data for IL-10R expression are shown on Fig. 3A.
Exhaled nitric oxide measurements. The concentration of nitric
oxide in the exhaled air was assessed with the use of chemilumines-
cence analyzer NOA™ 280i (Sievers, USA) according to American
Thoracic Society recommendations as described previously [33,34].
In brief, the analyzer was fitted with a biofeedback display unit to
provide visual guidance for the subject to maintain the pressure and
exhalation flow within a certain range. Subjects exhaled slowly from
total lung capacity over 30 s with an exhalation flow of 50 ml/s. The
mean of three separate measurements was used for analysis.
Statistical analysis. We used Kruskal-Wallis ANOVA and Mann-
Whitney nonparametric tests to analyse statistically significant differ-
ences among groups. Nonparametric Wilcoxon test was used to
analyse the pre- and after-treatment values. The correlations were
examined by Spearman rank correlation coefficient. In all tests, sta-
tistically significant results were identified by a p value of <0.05.
Results
CD16 expression is decreased in BMs 
of asthmatic patients 
The use of a combination of CD14 and CD16 mono-
clonal antibodies revealed dramatically different BM
phenotype profiles between both untreated and treat-
ed asthmatics and healthy subjects. First, based on
unstained, isotype and FMO controls and different
densities of CD14 and CD16 staining observed in
healthy subjects, we delineated four distinct BM
subpopulations (Fig. 1A) Such phenotype was con-
sistent in all healthy controls, thus we set the addi-
tional quadrant markers (thick grey lines) separating
those subpopulations and kept them throughout the
study for further comparative analysis of BM pheno-
type in asthmatic patients (Fig. 1A, bottom panel). In
brief, we found that about 80% of BMs in healthy sub-
jects is characterized by the CD14low CD16high phe-
notype. In contrast to healthy controls, asthmatics'
BMs revealed mostly CD14low CD16dim and
CD14low CD16 high phenotype. Detailed percentage
distributions of BMs with different intensities of CD14
and CD16 expression are presented in Table 2.
Notably, in asthmatics, there was no clear distinction
between CD14low CD16dim and CD14low CD16high
BMs. Thus, in order to more precisely quantify the
phenotypic differences among subjects, we analyzed
total antigen densities for both CD14 and CD16 (Fig.
1B). BMs from steroid-naive and steroid-treated asth-
matics exhibited significantly decreased CD16 expres-
sion as compared with healthy subjects (p<0.05 for
both groups). In contrast, CD14 presented with a dif-
ferent pattern of expression. Although we did not find
statistically significant differences among groups,
steroid-treated asthmatics tended to express more
CD14 than steroid-naive patients, and, to a lesser
extent, healthy subjects.
Short-term ICS administration results 
in decrease of CD16 expression and enhance-
ment of CD14 expression
To investigate the potential role of CS treatment in
modulation of CD14 and CD16 expression on the sur-
face of BMs, in four of six steroid-naive asthmatics the
follow-up flow-cytometric analysis was performed
after 7 days of treatment with 800 µg of inhaled budes-
onide. As depicted in Fig. 1C, short-term ICS treat-
ment exerted opposing effects on CD14 and CD16 BM
expression. BMs tested showed a decrease in expres-
sion of CD16 and enhancement of CD14 expression
(p<0.05, for both molecules).
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Table 2. Percentage distribution of bronchial macrophages among
BMs with different intensities of CD14 and CD16 expression.
Phenotypic division of BMs refers to varying levels of CD14 and CD16
expression as depicted on Fig.1A with the use of grey quadrant lines.
Values are presented as medians with 25th-75th percentiles..
CD16, but not CD14, expression in BMs
inversely correlates with exhaled nitric oxide
and sputum eosinophilia
As both CD16 and CD14 molecules appeared to be
modulated in asthmatic patients, we investigated
whether correlations between their expression and
markers of asthma severity exist. In fact, significant
inverse correlations were observed between CD16
expression and exhaled nitric oxide (eNO) (r=-0.74,
p<0.05), and sputum eosinophilia (r=-0.5, p<0.05, Fig.
2A). In contrast, no significant correlations were found
when similar analyses were performed for CD14 (Fig.
2B). Congruently with the observations made by
Jatakanon et al. [35],  exhaled nitric oxide and sputum
eosinophilia in studied subjects correlated closely with
each other (r=0.58, p<0.05). 
BMs express substantial levels of IL-10R that
positively correlate with CD14 expression
Next we applied three-color flow cytometry to analyse
the expression of IL-10R on the surface of BMs with
different intensities of CD14 and CD16 expression.
Interestingly, in all three groups of patients we




Fig. 1. The analysis of CD14 and CD16
expression in BMs of healthy and asth-
matic subjects. A. Flow cytometric den-
sity plots characteristic for healthy and
asthmatic patients. Standard quadrants
(thin black lines) were created based on
isotype and CD14+ and CD16+ FMO
controls from healthy subjects (top
panel).  Additional thick grey quadrant
lines were drawn to delineate four dis-
tinct BM subpopulations based on the
FMO controls and the pattern of expres-
sion of CD14 and CD16 observed in
healthy subjects (bottom left density
plot). Thus CD14low CD16dim BMs are
in the lower left quadrant, CD14high
CD16dim in the upper left quadrant,
CD14high CD16high in the upper right
quadrant, and CD14low CD16high in the
lower right quadrant. B. The summary of
analyses of CD16 and CD14 expression
by BMs in asthmatic and healthy sub-
jects. The results are for the geometric
mean fluorescence intensity (MFI) of the
CD16+ (left column) and CD14+ (right
column) BMs, reported as the median
with 25th-75th percentile. Statistically
significant differences between groups
are indicated with asterisks (p<0.05).
Asthmatic ICS (-) - asthmatic patients
not receiving ICS. Asthmatic ICS (+) -
asthmatic patients treated with ICS. C.
The effects of 7-day administration of
800 µg of inhaled budesonide in steroid-
naive asthmatic patients on the levels of
CD16 and CD14 on the surface of BMs.
The results are for the MFI of the CD16+
(left column) and CD14+ (right column)
BMs, reported as the median with 25th-
75th percentile (n=4). Statistically sig-
nificant differences between groups are
indicated with asterisks (p<0.05)
observed a similar profile of IL-10R distribution
between BM subpopulations. As depicted in Fig. 3A,
and summarized in Fig. 3B, IL-10R was found on the
surface of CD16dim CD14high and CD16high
CD14high BMs at two- to ten-fold higher levels than
on CD16dim CD14low and CD16high CD14low BMs.
Moreover, we found a positive correlation between
CD14 and IL-10R expression (r=0.53, p<0.05, Fig. 3C).
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Fig. 3A. Flow cytometric histograms representing the levels of IL-10R expression in BMs with different intensities of CD14 and CD16
staining in representative samples of asthmatic and healthy subjects. Values refer to MFI of IL-10R expression by marked BMs.
Fig. 2. A. Linear regression
analysis of BM CD16 expression
and exhaled nitric oxide (eNO)
levels (left panel) and sputum
eosinophils (%) (right panel). A
significant (p<0.05) negative cor-
relation was observed between
CD16 expression and eNO levels
r=-0.74) and percent of sputum
eosinophils (r=-0.5). B. Similar
analysis performed for CD14 did
not reveal statistically significant
correlations: r=-0.15 for eNO (left
panel, p>0.05), and, r=0.07 for
sputum eosinophils (%) (right
panel, p>0.05). 
Comparative analysis of IL-10R expression on cor-
responding BM subpopulations in healthy and asth-
matic patients did not reveal statistically significant
differences among groups. However, we observed
that predominantly CD14+ BMs of healthy individu-
als tended to express more IL-10R as compared with
both asthmatic groups. Finally, we investigated the
effects of short-term ICS treatment on modulation of
macrophage IL-10R expression in steroid-naive
asthmatics. Surprisingly, we observed varying
changes in IL-10R expression, which resulted in a
lack of significant difference between pre- and after-
treatment values for total BM population as well as
single BM subsets (Fig. 3D and data not shown).
Moreover, we did not find statistically significant
correlations between levels of IL-10R and eNO and
sputum eosinophilia (r=0.15, p>0.05, and, r=0.17,
p>0.05, respectively).
Low levels of IL-7R and IL-4R on BMs 
Three-color flow cytometry analysis revealed that
BMs of all studied subjects expressed both IL-7R and
IL-4R at significantly lower levels than IL-10R. Inter-
estingly, in contrast to IL-10R, IL-7R and IL-4R
expression was equally distributed among all BM sub-
populations (Fig. 4). Moreover, we did not observe any
differences in IL-7R and IL-4R among asthmatic and
healthy individuals. Finally, the effects of short-term
ICS treatment on the levels of IL-7R and IL-4R were
negligible (data not shown).
Discussion
In our study we provided novel phenotypic character-
istic of BMs with regard to cytokine receptor expres-
sion. Notably, we correlated data concerning BMs with
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B
Fig. 3B-D. B. The summary of analyses of IL-10R expression by BMs in asthmatic and healthy subjects. The results are for the MFI of
the IL-10R+ BMs, reported as the median with 25th-75th percentile. Statistically significant differences between groups are indicated with
asterisks (p<0.05). C. Linear regression analysis of BM IL-10R expression and CD16 expression. A significant (p<0.05) positive corre-
lation was observed between IL-10R expression and CD16 expression (r=0.53). D. The effects of 7-day administration of 800 µg of budes-
onide in steroid-naïve asthmatic patients on the levels of IL-10R on the surface of BMs. The results are for the MFI of the IL-10R+ BMs,
reported as median with 25th-75th percentile (n=4). 
non-invasive markers of allergic inflammation. Our
results show that eosinophilic inflammation in asth-
matic patients is closely associated with decreased
CD16 expression on BMs. CD16, together with CD64,
participates in phagocytosis of opsonized particles or
of immune complexes; thus, its decreased expression
in asthmatics suggests that allergic inflammation may
disturb phagocytic activity of BMs. The results pre-
sented here in moderate asthmatics supplement the
findings reported by Alexis et al. in mild asthmatics,
i.e., dysfunctional phagocytosis of IgG-opsonized
yeast and decreased CD64 expression [16]. 
We demonstrated that ICS treatment resulted in sig-
nificant reduction of CD16 expression on BMs. Our
results are in line with reports of other researchers
investigating the effects of CS treatment on peripheral
blood monocytes. Fingerle-Rowson et al. and Dayyani
F et al. reported a significant decrease in numbers of
CD16+ monocytes in patients treated for multiple scle-
rosis with high doses of glucocorticoid therapy [36,37]. 
As we have shown in our study, CD14+ expression
on BMs positively correlates with expression of the
receptor for IL-10. Surprisingly, short-term ICS
administration did not result in unambiguous enhance-
ment of IL-10R expression despite enhancement of
CD14 expression. Similarly, we did not find signifi-
cantly higher IL-10R levels on BMs of asthmatic
patients that received long-term ICS therapy. Thus, it
is possible that the effects of ICS on IL-10R expres-
sion might be influenced by other cells and/or inflam-
matory mediators accounting for chronic persistence
of allergic airway inflammation. 
IL-10 has numerous anti-inflammatory effects and
its action is mediated by IL-10R [17,38]. Lim et al.
reported detectable IL-10R expression in alveolar
macrophages but not epithelial cells collected from
BAL [21]. Those authors did not find differences in
macrophage IL-10R expression between asthmatic and
healthy subjects. Our results suggest that healthy sub-
jects' BMs (especially CD14+) tend to express more IL-
10R as compared to asthmatic subjects. Further studies
are warranted to investigate whether BMs of asthmatic
patients may indeed have less pronounced functional
response to IL-10. Our work extends the observations of
Lim et al. to BMs as we have shown that those cells
express substantial levels of receptors for IL-10. This
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Fig. 4. The summary of analyses of 
IL-7R and IL-4R expression by BMs in
asthmatic and healthy subjects. The
results are for the MFI of the IL-7R+
(top panel) and IL-4R+ (lower panel)
BMs, reported as the median with 25th-
75th percentile.
could be of clinical importance as BMs constitute a
large population of airway cells that could benefit from
either therapy stimulating local IL-10 production or
even potential IL-10 administration [39-41].
Differential expression of IL-10R by CD14+ and
CD14-negative BMs suggests that not all BMs play
identical roles in regulation of allergic inflammation.
Whilst CD14+ BMs constitute only a small percentage
of the total population, they seem to be most suscepti-
ble to IL-10-mediated signals. Detailed functional
studies are needed to investigate whether BMs charac-
terized by monocyte-associated phenotype (CD14+)
may play a more significant role in immunoregulation
of allergic inflammation as compared with the majori-
ty of CD14-negative BMs. 
Detection of low levels of IL-4R and IL-7R on the
surface of BMs is in line with similar results obtained
in peripheral blood monocytes [42], and our own
observations]. Thus, it cannot be solely associated with
presumable laboratory artifacts caused by, for exam-
ple, isolation procedures [30]. In fact, many studies
show that the use of DTT in sputum preparation may
influence the obtained results [43,44]. On the other
hand, detection of low levels of IL-4R and IL-7R,
despite the use of a technical protocol identical to that
for IL-10R analysis, clearly indicates the differential
expression of those three receptors. The functional rel-
evance of our findings regarding the expression of IL-
4R and IL-7R on BMs remains to be elucidated in fur-
ther in vitro studies. 
In summary, our data demonstrate that BM pheno-
type is affected by both airway inflammation process
and ICS treatment. Moreover, we suggest that BMs are
capable of responding to immunomodulatory signals,
mainly those mediated by IL-10.  
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